Difference between revisions of "Amsacrine (Amsidine)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Vesicant chemotherapy" to "Category:Vesicant") Tags: mobile edit mobile web edit |
Warner-admin (talk | contribs) m (Text replacement - "Category:DNA synthesis inhibitors" to "Category:Human DNA synthesis inhibitors") |
||
| Line 22: | Line 22: | ||
[[Category:Vesicant]] | [[Category:Vesicant]] | ||
| − | [[Category:DNA synthesis inhibitors]] | + | [[Category:Human DNA synthesis inhibitors]] |
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
[[Category:Orphan drug]] | [[Category:Orphan drug]] | ||
[[Category:Health Canada approved drugs]] | [[Category:Health Canada approved drugs]] | ||
Revision as of 18:33, 27 February 2020
General information
Class/mechanism: Synthetic acridine-derivate. Exact mechanism unclear; amsacrine binds to DNA by intercalation and external electrostatic binding, which inhibits DNA synthesis and causes DNA fragmentation.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Also known as
- Code names: CI-880, SN-11841
- Generic names: acridinyl anisidide, AMSA, Cain's acridine, m-AMSA
- Brand names: Amekrin, Amsa P-D, Amsidine, Amsidyl, Lamasine